GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

Search

Ocugen Inc

Chiusa

1.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.99

Massimo

1.08

Metriche Chiave

By Trading Economics

Entrata

-1.5M

-15M

Vendite

717K

1.5M

EPS

-0.05

Margine di Profitto

-1,036.462

Dipendenti

95

EBITDA

-350K

-14M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+508.65% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

82M

287M

Apertura precedente

1.01

Chiusura precedente

1.01

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Ocugen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 giu 2025, 20:51 UTC

Utili

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 20:48 UTC

Discorsi di Mercato

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 giu 2025, 19:31 UTC

Discorsi di Mercato

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 giu 2025, 19:19 UTC

Discorsi di Mercato

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 giu 2025, 19:16 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 giu 2025, 18:39 UTC

Discorsi di Mercato
Utili

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 giu 2025, 18:29 UTC

Discorsi di Mercato

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 giu 2025, 18:18 UTC

Discorsi di Mercato

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 giu 2025, 18:16 UTC

Discorsi di Mercato

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 giu 2025, 17:16 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 giu 2025, 17:08 UTC

Utili

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 giu 2025, 16:52 UTC

Acquisizioni, Fusioni, Takeovers

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 giu 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

27 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

27 giu 2025, 15:59 UTC

Discorsi di Mercato

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 giu 2025, 15:56 UTC

Discorsi di Mercato

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Confronto tra pari

Modifica del prezzo

Ocugen Inc Previsione

Obiettivo di Prezzo

By TipRanks

508.65% in crescita

Previsioni per 12 mesi

Media 6.33 USD  508.65%

Alto 8 USD

Basso 4 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ocugen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.6818 / 0.74Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.